

Michael Davis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4131061/publications.pdf>

Version: 2024-02-01

30
papers

4,486
citations

516710

16
h-index

454955

30
g-index

31
all docs

31
docs citations

31
times ranked

6331
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing) Tj ETQq1 1 0.784314 rgBT /Overloc	2.5	23
2	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU International, 2020, 125, 506-514.	2.5	32
3	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. European Urology, 2020, 77, 320-330.	1.9	107
4	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. British Journal of Cancer, 2020, 123, 1063-1070.	6.4	15
5	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. BMJ Open, 2020, 10, e036024.	1.9	7
6	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	2.8	22
7	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. Journal of Clinical Epidemiology, 2019, 113, 200-213.	5.0	6
8	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. Cancer Causes and Control, 2018, 29, 383-388.	1.8	15
9	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology, 2018, 96, 35-46.	5.0	16
10	Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial. Cancer Causes and Control, 2017, 28, 877-888.	1.8	2
11	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. European Urology, 2017, 71, 381-388.	1.9	41
12	Radiotherapy for Prostate Cancer: is it "what you do" or "the way that you do it"? A UK Perspective on Technique and Quality Assurance. Clinical Oncology, 2016, 28, e92-e100.	1.4	7
13	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine, 2016, 375, 1415-1424.	27.0	2,101
14	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine, 2016, 375, 1425-1437.	27.0	962
15	Investigating the prostate specific antigen, body mass index and age relationship: is an age-adjusted BMI-adjusted PSA model clinically useful?. Cancer Causes and Control, 2016, 27, 1465-1474.	1.8	17
16	Gleason drift in the <sc>NIHR P</sc>rotec<sc>T</sc> study. Histopathology, 2015, 66, 438-446.	2.9	9
17	Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study. Journal of the National Cancer Institute, 2015, 107, .	6.3	146
18	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 1109-1118.	10.7	205

#	ARTICLE	IF	CITATIONS
19	Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. <i>Cancer Causes and Control</i> , 2013, 24, 39-45.	1.8	8
20	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. <i>BMJ: British Medical Journal</i> , 2012, 344, d7894-d7894.	2.3	211
21	Associations of Lifestyle Factors and Anthropometric Measures with Repeat PSA Levels During Active Surveillance/Monitoring. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1877-1885.	2.5	19
22	A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. <i>Cancer Causes and Control</i> , 2012, 23, 907-917.	1.8	32
23	The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 316-27.	0.4	9
24	Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts. <i>European Urology</i> , 2010, 57, 446-452.	1.9	12
25	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. <i>Science Translational Medicine</i> , 2010, 2, 62ra92.	12.4	140
26	Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2833-2838.	2.5	20
27	Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1632-1642.	2.5	142
28	Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2874-2881.	2.5	64
29	Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: A case-control study nested within the UK population-based ProtecT (Prostate testing for) Tj ETQq1 1 0.78431 4 rgBT1/5 Overlo	2.5	43
30	Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2325-2336.	2.5	83